Cancer Market Facts

The AntiCancer PDOX team has come together with a common goal –
to improve the outcomes of cancer therapy.

A Growing Problem

Unfortunately, the worldwide incidence of cancer is expected to grow 75% by 2030.  As a result, the cancer medicine market will reach $124.9B growing at a 7% Compound Annual Growth Rate (CAGR) by 2018.  AntiCancer PDOX is targeting this market and the following sub-markets*:

  1. Precision Medicine, which will reach $88B by 2022.
  2. Personalized oncological and medical testing and analysis, which grew to $21B in 2016.
  3. Cancer and tumor profiling, which will reach $35B by 2018, growing at a CAGR of 18.5%.

Key drivers:

  • Personalized treatment
  • Technological innovation
  • Gene sequencing
  • Precise imaging
  • Government support & regulation

We have the right team. AntiCancer PDOX Founder Robert Hoffman is a world-leading cancer researcher with more than 50 years experience. The team of AntiCancer scientists in San Diego has more than 30 years experience and 800+ peer-reviewed papers, ~500 of them on mouse models.  Two prominent oncologists from UCLA serve on our board and are involved in our work on a daily basis.  We have already received and tested ~200 tumors from the UCLA sarcoma facility.

Our business is already thriving. AntiCancer PDOX is currently targeting the Tumor Banking and Pharmaceutical Discovery markets. Banked tumors are leveraged for future revenue. To date, more than 600 drug discovery contracts have benefited from our technique.  Our eventual goal is to reach patients by targeting oncologists, surgeons and advocacy groups.

Services Offered:

  • Drug Discovery
  • Custom In Vivo Study Design
  • PDOX Fluorescent Imaging
  • Tumor Banking
  • Custom In Vitro Study Design

We have the technology. AntiCancer PDOX was founded to address these challenges.  The PDOX® technique improves cancer-therapy outcomes by individualizing the treatment for each patient. AntiCancer PDOX owns proprietary technology plus imaging patents with several patents pending.  We have the technology and capabilities to start helping patients now.

If you are interested in learning more about the cancer market and the PDOX opportunity, please contact us at

* Sources: Markets and Markets Research, PricewaterhouseCoopers, International Agency for Cancer Research, Global Precision Medicine Market.